Procedures
ADVERSE EVENTS
The study design is shown in Study design*Indicates that colonoscopy was done at that timepoint.Study visits were planned every 8 weeks for 104 weeks (end of study visit). The end of study visit took place earlier in case of early study termination. In case of relapse, the end of study visit occurred between week 100 and week 108, at the date closest to week 104. At each visit, patients underwent clinical examination; recording of adverse events; CDAI calculation; quality-of-life assessment by EQ-5D,Infliximab levels and anti-infliximab antibodies were determined by TNF-coated ELISA and by the anti-lambda drug-tolerant ELISA, respectively, as previously described.